Article Text
Abstract
Infliximab, an antitumour necrosis factor alpha (TNF-alpha)agent, is a cornerstone of treatment of inflammatory bowel disease with a favourable and well-tolerated side effect profile. While the majority of side effects associated with infliximab have been well established, the pathophysiology of infliximab-associated thrombosis remains controversial and poorly defined. We present a case of a young woman with ulcerative colitis who presented with a right ventricular thrombus and bilateral pulmonary emboli after initiation of infliximab and was subsequently found to have underlying factor V Leiden and prothrombin gene mutation. Clinicians should be aware of this potential adverse event associated with anti-TNF agents, especially in individuals with predisposing prothrombotic mutations such as factor V Leiden or prothrombin gene mutation.
- venous thromboembolism
- gastrointestinal system
- immunological products and vaccines
- inflammatory bowel disease
- pulmonary embolism
Statistics from Altmetric.com
Footnotes
Contributors JAO and AI were the primary authors in this case report writing up the case and discussion, Contributing authors CH and RB both assisted with the writing process and intellectual content, article design and revision and editing of article. RB was responsible for direct pt care.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.